S&P 500   4,568.14 (-0.04%)
DOW   36,130.70 (-0.20%)
QQQ   386.23 (-0.02%)
AAPL   193.04 (+1.91%)
MSFT   371.46 (+0.63%)
META   317.59 (-0.76%)
GOOGL   130.55 (+0.99%)
AMZN   146.71 (+1.29%)
TSLA   238.34 (+1.17%)
NVDA   462.34 (+1.59%)
NIO   7.41 (+1.23%)
BABA   72.46 (-0.78%)
AMD   118.01 (-0.47%)
T   17.28 (+3.72%)
F   10.63 (-0.65%)
MU   73.63 (-0.89%)
CGC   0.66 (-12.80%)
GE   120.43 (-0.91%)
DIS   90.52 (-1.62%)
AMC   7.06 (-5.74%)
PFE   29.21 (-0.24%)
PYPL   57.42 (-4.06%)
XOM   100.95 (-1.44%)
S&P 500   4,568.14 (-0.04%)
DOW   36,130.70 (-0.20%)
QQQ   386.23 (-0.02%)
AAPL   193.04 (+1.91%)
MSFT   371.46 (+0.63%)
META   317.59 (-0.76%)
GOOGL   130.55 (+0.99%)
AMZN   146.71 (+1.29%)
TSLA   238.34 (+1.17%)
NVDA   462.34 (+1.59%)
NIO   7.41 (+1.23%)
BABA   72.46 (-0.78%)
AMD   118.01 (-0.47%)
T   17.28 (+3.72%)
F   10.63 (-0.65%)
MU   73.63 (-0.89%)
CGC   0.66 (-12.80%)
GE   120.43 (-0.91%)
DIS   90.52 (-1.62%)
AMC   7.06 (-5.74%)
PFE   29.21 (-0.24%)
PYPL   57.42 (-4.06%)
XOM   100.95 (-1.44%)
S&P 500   4,568.14 (-0.04%)
DOW   36,130.70 (-0.20%)
QQQ   386.23 (-0.02%)
AAPL   193.04 (+1.91%)
MSFT   371.46 (+0.63%)
META   317.59 (-0.76%)
GOOGL   130.55 (+0.99%)
AMZN   146.71 (+1.29%)
TSLA   238.34 (+1.17%)
NVDA   462.34 (+1.59%)
NIO   7.41 (+1.23%)
BABA   72.46 (-0.78%)
AMD   118.01 (-0.47%)
T   17.28 (+3.72%)
F   10.63 (-0.65%)
MU   73.63 (-0.89%)
CGC   0.66 (-12.80%)
GE   120.43 (-0.91%)
DIS   90.52 (-1.62%)
AMC   7.06 (-5.74%)
PFE   29.21 (-0.24%)
PYPL   57.42 (-4.06%)
XOM   100.95 (-1.44%)
S&P 500   4,568.14 (-0.04%)
DOW   36,130.70 (-0.20%)
QQQ   386.23 (-0.02%)
AAPL   193.04 (+1.91%)
MSFT   371.46 (+0.63%)
META   317.59 (-0.76%)
GOOGL   130.55 (+0.99%)
AMZN   146.71 (+1.29%)
TSLA   238.34 (+1.17%)
NVDA   462.34 (+1.59%)
NIO   7.41 (+1.23%)
BABA   72.46 (-0.78%)
AMD   118.01 (-0.47%)
T   17.28 (+3.72%)
F   10.63 (-0.65%)
MU   73.63 (-0.89%)
CGC   0.66 (-12.80%)
GE   120.43 (-0.91%)
DIS   90.52 (-1.62%)
AMC   7.06 (-5.74%)
PFE   29.21 (-0.24%)
PYPL   57.42 (-4.06%)
XOM   100.95 (-1.44%)

Progyny Stock Price, News & Analysis (NASDAQ:PGNY)

$35.02
-0.17 (-0.48%)
(As of 02:45 PM ET)
Compare
Today's Range
$34.78
$35.27
50-Day Range
$29.51
$35.19
52-Week Range
$28.03
$44.95
Volume
446,466 shs
Average Volume
801,846 shs
Market Capitalization
$3.36 billion
P/E Ratio
67.35
Dividend Yield
N/A
Price Target
$47.00

Progyny MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
34.6% Upside
$47.00 Price Target
Short Interest
Bearish
6.87% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.68mentions of Progyny in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
19.30%
From $0.57 to $0.68 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.85 out of 5 stars

Medical Sector

56th out of 949 stocks

Miscellaneous Health & Allied Services, Not Elsewhere Classified Industry

1st out of 6 stocks


PGNY stock logo

About Progyny Stock (NASDAQ:PGNY)

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

PGNY Stock Price History

PGNY Stock News Headlines

Countries Are Investing Heavily Into Securing Energy Independence
There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.
Does Progyny (PGNY) have a Long Runway for Growth?
Progyny: Market Underappreciating Excellent Quarter
The Battery Metal Nobody Told You About
According to McKinsey and Company, the battery storage market is growing rapidly, especially with the transition to clean, renewable energy. Lithium-ion batteries still grab most of the headlines. But analysts now call safe and long-lasting batteries made with vanadium "the future of battery tech."
Analyst Ratings for Progyny
Progyny Inc PGNY
Progyny, Inc. Announces Third Quarter 2023 Results
Progyny: 4 Reasons I Bought This Stock
Progyny (PGNY): Unveiling Its True Value
Check Out What Whales Are Doing With PGNY
3 Reasons Growth Investors Will Love Progyny (PGNY)
See More Headlines
Receive PGNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Progyny and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/05/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/26/2024

Industry, Sector and Symbol

Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PGNY
Fax
N/A
Employees
393
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$47.00
High Stock Price Target
$57.00
Low Stock Price Target
$34.00
Potential Upside/Downside
+33.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$30.36 million
Pretax Margin
5.67%

Debt

Sales & Book Value

Annual Sales
$786.91 million
Cash Flow
$0.35 per share
Book Value
$4.06 per share

Miscellaneous

Free Float
82,419,000
Market Cap
$3.37 billion
Optionable
Not Optionable
Beta
1.51

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report














PGNY Stock Analysis - Frequently Asked Questions

Should I buy or sell Progyny stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Progyny in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PGNY shares.
View PGNY analyst ratings
or view top-rated stocks.

What is Progyny's stock price target for 2024?

8 analysts have issued 12 month price objectives for Progyny's shares. Their PGNY share price targets range from $34.00 to $57.00. On average, they predict the company's stock price to reach $47.00 in the next year. This suggests a possible upside of 34.6% from the stock's current price.
View analysts price targets for PGNY
or view top-rated stocks among Wall Street analysts.

How have PGNY shares performed in 2023?

Progyny's stock was trading at $31.15 on January 1st, 2023. Since then, PGNY shares have increased by 12.1% and is now trading at $34.92.
View the best growth stocks for 2023 here
.

When is Progyny's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our PGNY earnings forecast
.

How were Progyny's earnings last quarter?

Progyny, Inc. (NASDAQ:PGNY) announced its earnings results on Tuesday, November, 7th. The company reported $0.16 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.05. The firm had revenue of $280.90 million for the quarter, compared to analyst estimates of $271.20 million. Progyny had a trailing twelve-month return on equity of 11.64% and a net margin of 5.03%. The business's revenue for the quarter was up 36.8% compared to the same quarter last year. During the same period last year, the firm earned $0.13 earnings per share.

What guidance has Progyny issued on next quarter's earnings?

Progyny updated its fourth quarter earnings guidance on Tuesday, November, 7th. The company provided earnings per share guidance of $0.10-$0.11 for the period, compared to the consensus earnings per share estimate of $0.11. The company issued revenue guidance of $268.3-$276.3 million, compared to the consensus revenue estimate of $274.26 million.

What is David Schlanger's approval rating as Progyny's CEO?

25 employees have rated Progyny Chief Executive Officer David Schlanger on Glassdoor.com. David Schlanger has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Progyny own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Progyny investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Marvell Technology (MRVL), Alteryx (AYX), Micron Technology (MU), AbbVie (ABBV), Home Depot (HD), Advanced Micro Devices (AMD).

When did Progyny IPO?

(PGNY) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.

Who are Progyny's major shareholders?

Progyny's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Clearbridge Investments LLC (4.11%), Fred Alger Management LLC (3.35%), Jennison Associates LLC (2.84%), JPMorgan Chase & Co. (2.56%), Riverbridge Partners LLC (1.97%) and Baillie Gifford & Co. (1.72%). Insiders that own company stock include Beth C Seidenberg, Cheryl Scott, David J Schlanger, Group Holdings (Sbs) Advis Tpg, Jennifer Bealer, Kevin K Gordon, Lisa Greenbaum, Mark S Livingston, Norman Payson, Perkins Caufield & Bye Kleiner, Peter Anevski, Robert Michael Floyd and Tpg Gp A, Llc.
View institutional ownership trends
.

How do I buy shares of Progyny?

Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:PGNY) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -